Abstract
In this article we review the role of vascular endothelial growth factor (VEGF) in colon cancer growth and the underlying mechanisms. Angiogenesis, the growth of new capillary blood vessels in the body, is critical for tissue injury healing and cancer growth. In 1971, Judah Folkman proposed the concept that tumor growth beyond 2 mm is critically dependent on angiogenesis. Tumors including colon cancers release angiogenic growth factors that stimulate blood vessels to grow into the tumors thus providing oxygen and nutrients that enable exponential growth. VEGF is the most potent angiogenic growth factor. Several studies have highlighted the role of VEGF in colon cancer, specifically in the stimulation of angiogenesis. This role of VEGF is strongly supported by studies showing that inhibition of VEGF using the blocking antibody, bevacizumab, results in decreased angiogenesis and abrogation of cancer growth. In the United States, bevacizumab in combination with chemotherapy is FDA approved for the treatment of metastatic colon cancer. However, the source of VEGF in colon cancer tissue, the mechanisms of VEGF generation in colon cancer cells and the molecular pathways involved in VEGF mediated angiogenesis in colon cancer are not fully known. The possibility that VEGF directly stimulates cancer cell growth in an autocrine manner has not been explored in depth.
Keywords: Colon cancer, VEGF, angiogenesis, cancer cell growth.
Current Pharmaceutical Design
Title:VEGF and Colon Cancer Growth Beyond Angiogenesis: Does VEGF Directly Mediate Colon Cancer Growth Via a Non-angiogenic Mechanism?
Volume: 20 Issue: 7
Author(s): Amrita Ahluwalia, Michael K. Jones, Tamara Matysiak-Budnik and Andrzej S. Tarnawski
Affiliation:
Keywords: Colon cancer, VEGF, angiogenesis, cancer cell growth.
Abstract: In this article we review the role of vascular endothelial growth factor (VEGF) in colon cancer growth and the underlying mechanisms. Angiogenesis, the growth of new capillary blood vessels in the body, is critical for tissue injury healing and cancer growth. In 1971, Judah Folkman proposed the concept that tumor growth beyond 2 mm is critically dependent on angiogenesis. Tumors including colon cancers release angiogenic growth factors that stimulate blood vessels to grow into the tumors thus providing oxygen and nutrients that enable exponential growth. VEGF is the most potent angiogenic growth factor. Several studies have highlighted the role of VEGF in colon cancer, specifically in the stimulation of angiogenesis. This role of VEGF is strongly supported by studies showing that inhibition of VEGF using the blocking antibody, bevacizumab, results in decreased angiogenesis and abrogation of cancer growth. In the United States, bevacizumab in combination with chemotherapy is FDA approved for the treatment of metastatic colon cancer. However, the source of VEGF in colon cancer tissue, the mechanisms of VEGF generation in colon cancer cells and the molecular pathways involved in VEGF mediated angiogenesis in colon cancer are not fully known. The possibility that VEGF directly stimulates cancer cell growth in an autocrine manner has not been explored in depth.
Export Options
About this article
Cite this article as:
Ahluwalia Amrita, Jones K. Michael, Matysiak-Budnik Tamara and Tarnawski S. Andrzej, VEGF and Colon Cancer Growth Beyond Angiogenesis: Does VEGF Directly Mediate Colon Cancer Growth Via a Non-angiogenic Mechanism?, Current Pharmaceutical Design 2014; 20 (7) . https://dx.doi.org/10.2174/1381612819999131218175905
DOI https://dx.doi.org/10.2174/1381612819999131218175905 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in the Medicinal Chemistry of α-Aminoboronic Acids, Amine-Carboxyboranes and Their Derivatives
Mini-Reviews in Medicinal Chemistry Non-Invasive Tests in Animal Models and Humans: A New Paradigm for Assessing Efficacy of Biologics Including Prebiotics and Probiotics
Current Pharmaceutical Design Other Future Targeting Therapy Beyond TNF-α Inhibitor in Patients with Spondyloarthropathy
Current Rheumatology Reviews Dendritic Cell Vaccine and Cancer Treatment: New Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) HumDLoc: Human Protein Subcellular Localization Prediction Using Deep Neural Network
Current Genomics FOXM1-Dependent Transcriptional Regulation of EZH2 Induces Proliferation and Progression in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
Current Pharmaceutical Design PIM1 Kinase as a Target in Prostate Cancer: Roles in Tumorigenesis, Castration Resistance, and Docetaxel Resistance
Current Cancer Drug Targets Targeted Therapy in Advanced Gastric Carcinoma: The Future is Beginning
Current Medicinal Chemistry MicroRNAs in the Intestine: Role in Renewal, Homeostasis, and Inflammation
Current Molecular Medicine Inhibitory Effect of Fruit Juices on the Doxorubicin Metabolizing Activity of Carbonyl Reductase 1
Drug Metabolism Letters Novel 1,3,4-Triaryl Pyrazoles: Synthesis, QSAR Studies and Cytotoxicity against Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Modulation of Reactive Oxygen Species in Cancer Treatment
Current Drug Targets Military Risk Factors for Cognitive Decline, Dementia and Alzheimer’s Disease
Current Alzheimer Research Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design HER-2 Positive Breast Cancer: What Else Beyond Trastuzumab-Based Therapy?
Anti-Cancer Agents in Medicinal Chemistry Retraction Notice: The Benefits and Risks of Different Therapies in Preventing Postoperative Nausea and Vomiting in Patients Undergoing Thyroid Surgery
Current Drug Safety Cathelicidins: Peptides with Antimicrobial, Immunomodulatory, Anti- Inflammatory, Angiogenic, Anticancer and Procancer Activities
Current Protein & Peptide Science An update on Anti-inflammatory Compounds: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets